HIF3A: A Key Protein Regulating Oxygen Homeostasis (G64344)

Target Name: HIF3A

NCBI ID: G64344

HIF3A

HIF3A: A Key Protein Regulating Oxygen Homeostasis

HIF3A, also known as hypoxia inducible factor 3 alpha subunit, is a protein that plays a crucial role in the regulation of oxygen homeostasis in various organisms. It is a key player in the hypoxia response, which is a critical mechanism that allows organisms to adapt to changes in oxygen levels in their environment.

HIF3A is a subunit of the hypoxia inducible factor (HIF) family, which is a group of proteins that are involved in the regulation of oxygen homeostasis. The HIF family of proteins was identified as a potential drug target due to its involvement in various diseases, including anemia, cancer, and neurodegenerative diseases.

One of the main functions of HIF3A is to be transcribed and translated into protein. It can bind to the promoter region of the HIF gene, thereby initiating gene expression. Under hypoxic conditions, HIF3A can inhibit HIF gene transcription by binding to oxygen molecules. This inhibitory effect is very important under hypoxic conditions because it prevents cells from overproliferating under hypoxic conditions, which can lead to tissue damage and disease.

In addition, HIF3A is also involved in regulating intracellular oxygen concentration. Under hypoxic conditions, HIF3A can bind to intracellular oxygen molecules, thereby inhibiting the release of oxygen molecules. This inhibitory effect is important for maintaining oxygen concentration balance within cells, as it prevents cells from overproliferating under hypoxic conditions, which can lead to tissue damage and disease.

The inhibitory effect of HIF3A is also involved in the occurrence and development of tumors. Under hypoxic conditions, HIF3A can bind to oxygen molecules in tumor cells, thereby inhibiting the release of oxygen molecules. This inhibitory effect is important for tumor cell growth and spread, as it prevents tumor cells from overproliferating under hypoxic conditions, leading to tumor progression and spread.

Inhibition of HIF3A is also involved in the development of neurodegenerative diseases. Under hypoxic conditions, HIF3A can bind to oxygen molecules in nerve cells, thereby inhibiting the release of oxygen molecules. This inhibitory effect is very important for the onset and development of neurodegenerative diseases because it prevents excessive proliferation of nerve cells under hypoxic conditions, which can lead to nerve cell damage and disease.

In summary, HIF3A is a very important protein that is involved in many physiological processes, including oxygen homeostasis, cancer and neurodegenerative diseases. Therefore, HIF3A is a potential drug target and biomarker, which can be targeted by small molecules to treat anemia, cancer, and neurodegenerative diseases.

Protein Name: Hypoxia Inducible Factor 3 Subunit Alpha

Functions: Acts as a transcriptional regulator in adaptive response to low oxygen tension. Acts as a regulator of hypoxia-inducible gene expression (PubMed:11573933, PubMed:16126907, PubMed:19694616, PubMed:20416395, PubMed:21069422). Functions as an inhibitor of angiogenesis in hypoxic cells of the cornea. Plays a role in the development of the cardiorespiratory system. May also be involved in apoptosis (By similarity)

The "HIF3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HIF3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets